After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, ...

Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...

Idelvion (coagulation factor IX [recombinant], albumin fusion protein) is a prescription drug used to treat and help prevent bleeding episodes in people with hemophilia B. Idelvion is given as an ...

HATTERSHEIM, Germany, July 3, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product ...

ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety ...

Credit: Getty Images. The Agency stated that it “erred in approving the indication for routine prophylaxis in children with hemophilia B” due to the Orphan Drug exclusivity. The Food and Drug ...

December 13, 2011 — Transfer of the factor IX gene into hepatocytes via peripheral vein infusion is effective against hemophilia B, report Amit C. Nathwani, MD, PhD, from University College London, ...

Hemophilia B, also known as Christmas disease, is a bleeding disorder. Its characteristic feature is a deficiency of clotting factor IX. This is a protein present in the blood that helps with ...

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...

Biogen Idec and Swedish Orphan Biovitrum (Sobi) announced positive results from B-LONG, a global, open-label, multi-center Phase 3 clinical study that evaluated the efficacy, safety and ...